ABSTRACT
To perform safe invasive procedures on patients on anticoagulation therapy, management
of the patient's anticoagulation status is mandatory. For patients on anticoagulation
therapy, a risk analysis of both the procedural risk of bleeding as well as the risk
to the patient from discontinuing anticoagulation needs to be performed. For procedures
at low risk of bleeding, the procedure may be performed with little change to the
patient's anticoagulation regimen. For procedures with significant bleeding risk,
however, anticoagulation will need to be held or reversed. Patients at high risk for
thromboembolic complications will require bridging therapy if anticoagulation is to
be withheld. In this article, a logical assessment of bleeding risk in patients undergoing
procedures is presented, and a review of anticoagulation and risk is discussed.
KEYWORDS
Anticoagulation - heparin - warfarin - bleeding
REFERENCES
- 1
Hirsh J, Bauer K A, Donati M B, Gould M, Samama M M, Weitz J I. American College of
Chest Physicians .
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical
Practice Guidelines (8th Edition).
Chest.
2008;
133(6, Suppl)
141S-159S
- 2
du Breuil A L, Umland E M.
Outpatient management of anticoagulation therapy.
Am Fam Physician.
2007;
75(7)
1031-1042
- 3
Raschke R A, Reilly B M, Guidry J R, Fontana J R, Srinivas S.
The weight-based heparin dosing nomogram compared with a “standard care” nomogram.
A randomized controlled trial.
Ann Intern Med.
1993;
119(9)
874-881
- 4
Kubalek R, Berlis A, Schwab M, Klisch J, Schumacher M.
Activated clotting time or activated partial thromboplastin time as the method of
choice for patients undergoing neuroradiological intervention.
Neuroradiology.
2003;
45(5)
325-327
- 5
Siskin G P, Reiner E, Stainken B F et al..
Activated clotting time as a screening test prior to catheter-based cardiovascular
procedures.
Catheter Cardiovasc Interv.
2001;
54(2)
191-195
- 6 Jeanne P. Shah MaS .Heparin-induced thrombocytopenia occurring after discontinuation
of heparin. Medscape Radiology. Available at: http://www.medscape.com/viewarticle/452276 Accessed April 23, 2003
- 7
Rajgopal R, Bear M, Butcher M K, Shaughnessy S G.
The effects of heparin and low molecular weight heparins on bone.
Thromb Res.
2008;
122(3)
293-298
- 8
Sørensen B, Ingerslev J.
A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic
response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex
concentrate.
Thromb Haemost.
2006;
96(4)
446-453
- 9
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. American College of
Chest Physicians .
Pharmacology and management of the vitamin K antagonists: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest.
2008;
133(6, Suppl)
160S-198S
- 10
Malloy P C, Grassi C J, Kundu S Standards of Practice Committee with Cardiovascular
and Interventional Radiological Society of Europe (CIRSE) Endorsement et al.
Consensus guidelines for periprocedural management of coagulation status and hemostasis
risk in percutaneous image-guided interventions.
J Vasc Interv Radiol.
2009;
20(7, Suppl)
S240-S249
- 11
Douketis J D, Berger P B, Dunn A S American College of Chest Physicians et al.
The perioperative management of antithrombotic therapy: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest.
2008;
133(6, Suppl)
299S-339S
- 12
Collins L J, Silverman D I, Douglas P S, Manning W J.
Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications
with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution.
Circulation.
1995;
92(2)
160-163
- 13
Gage B F, Waterman A D, Shannon W, Boechler M, Rich M W, Radford M J.
Validation of clinical classification schemes for predicting stroke: results from
the National Registry of Atrial Fibrillation.
JAMA.
2001;
285(22)
2864-2870
- 14
Go A S, Hylek E M, Chang Y et al..
Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do
randomized trials translate into clinical practice?.
JAMA.
2003;
290(20)
2685-2692
- 15
Singer D E, Albers G W, Dalen J E American College of Chest Physicians et al.
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest.
2008;
133(6, Suppl)
546S-592S
- 16
Levine M N, Hirsh J, Gent M et al..
Optimal duration of oral anticoagulant therapy: a randomized trial comparing four
weeks with three months of warfarin in patients with proximal deep vein thrombosis.
Thromb Haemost.
1995;
74(2)
606-611
- 17
Bonow R O, Carabello B A, Chatterjee K American College of Cardiology et al.
ACC/AHA 2006 Guidelines for the Management of Patients with Valvular Heart Disease:
A Report of the American College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management
of Patients with Valvular Heart Disease) Developed in Collaboration with the Society
of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography
and Interventions and the Society of Thoracic Surgeons.
J Am Coll Cardiol.
2006;
48(3)
e1-e148
- 18
Martinelli I, Mannucci P M, De Stefano V et al..
Different risks of thrombosis in four coagulation defects associated with inherited
thrombophilia: a study of 150 families.
Blood.
1998;
92(7)
2353-2358
- 19
Lyman G H, Khorana A A, Falanga A American Society of Clinical Oncology et al.
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism
prophylaxis and treatment in patients with cancer.
J Clin Oncol.
2007;
25(34)
5490-5505
Blaze W CookM.D.
Denver Health Medical Center, Radiology Specialists of Denver
777 Bannock Street, Denver, CO 80204-4597
eMail: blaze@blazecook.com
